Moderna and Merck’s Melanoma Vaccine Shows Promise in Reducing Cancer Recurrence and Spread
A recent phase 3 clinical trial has unveiled promising results for a personalized mRNA vaccine developed by Moderna and Merck, designed to combat high-risk melanoma. The experimental treatment, known as intismeran, when administered alongside Keytruda (pembrolizumab), has demonstrated significant potential in reducing both the recurrence of melanoma and its spread to other parts of the…
